Literature DB >> 9768659

Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.

R S Swerdloff1, C J Bagatell, C Wang, B D Anawalt, N Berman, B Steiner, W J Bremner.   

Abstract

GnRH antagonists plus testosterone (T) suppress LH and FSH levels and inhibit spermatogenesis to azoospermia or severe oligozoospermia. High-dose T treatment alone has been shown to be an effective male contraceptive (contraceptive efficacy rate of 1.4 per 100 person yr). Combined GnRH antagonist and T induces azoospermia more rapidly and at a higher incidence than T alone; this combination has therefore been proposed as a prototype male contraceptive. However, because GnRH antagonists are expensive to synthesize and difficult to deliver, it would be desirable to rapidly suppress sperm counts to low levels with GnRH antagonist plus T and maintain azoospermia or severe oligozoospermia with T alone. In this study, 15 healthy men (age 21-41 yr) with normal semen analyses were treated with T enanthate (TE) 100 mg im/week plus 10 mg Nal-Glu GnRH antagonist sc daily for 12 weeks to induce azoospermia or severe oligozoospermia. At 12-16 weeks, 10 of 15 subjects had zero sperm counts, and 14 of 15 had sperm counts less than 3 x 10(6)/mL. The 14 who were suppressed on combined treatment were maintained on TE alone (100 mg/week im) for an additional 20 weeks. Thirteen of 14 subjects in the TE alone phase had sperm counts maintained at less than 3 x 10(6)/mL for 20 weeks. Ten remained persistently azoospermic or had sperm concentration of 0.1 x 10(6)/mL once during maintenance. Mean LH and FSH levels in the subjects were suppressed to 0.4+/-0.2 IU/L and 0.5+/-0.2 IU/L in the induction phase, which was maintained in the maintenance phase. The 1 subject who failed to suppress sperm counts during induction had serum LH and FSH reduced to 0.3 and 0.5 IU/L, respectively. The subject who failed to maintenance had LH and FSH suppressed to 1.0 and 0.2 IU/L, respectively, during the induction phase but these rose to 1.6 and 2.1 IU/L, respectively, during maintenance. Failure to suppress or maintain low sperm counts may be related to incomplete suppression of serum LH and FSH levels. We conclude that sperm counts suppressed with GnRH antagonist plus T can be maintained with relatively low dose TE treatment alone. This concept should be explored further in the development of effective, safe, and affordable hormonal male contraceptives.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9768659     DOI: 10.1210/jcem.83.10.5184

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Endocrine control of spermatogenesis: Role of FSH and LH/ testosterone.

Authors:  Suresh Ramaswamy; Gerhard F Weinbauer
Journal:  Spermatogenesis       Date:  2015-01-26

Review 2.  Hormonal approaches to male contraception.

Authors:  Christina Wang; Ronald S Swerdloff
Journal:  Curr Opin Urol       Date:  2010-11       Impact factor: 2.309

3.  Men with acquired hypogonadotropic hypogonadism treated with testosterone may be fertile.

Authors:  Andjela Drincic; Onur Karamanoglu Arseven; Ernesto Sosa; Moises Mercado; Peter Kopp; Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 4.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

5.  Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

6.  Use of Exogenous Testosterone for the Treatment of Male Factor Infertility: A Survey of Nigerian Doctors.

Authors:  Olufunmilade Akinfolarin Omisanjo; Stephen Odunayo Ikuerowo; Moruf Adekunle Abdulsalam; Sheriff Olabode Ajenifuja; Khadijah Adebisi Shittu
Journal:  Int J Reprod Med       Date:  2017-08-29

7.  Male contraception.

Authors:  Vivek Mathew; Ganapathi Bantwal
Journal:  Indian J Endocrinol Metab       Date:  2012-11

Review 8.  Endocrine aberrations of human nonobstructive azoospermia.

Authors:  Yong Tao
Journal:  Asian J Androl       Date:  2022 May-Jun       Impact factor: 3.054

Review 9.  Male Hormonal Contraception: Where Are We Now?

Authors:  Christina Wang; Mario P R Festin; Ronald S Swerdloff
Journal:  Curr Obstet Gynecol Rep       Date:  2016-01-29

Review 10.  Male contraception.

Authors:  Jing Chao; Stephanie T Page; Richard A Anderson
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2014-06-05       Impact factor: 5.237

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.